Aytu BioPharma terminates Metadate CD license with Lannett effective June 23
Aytu BioPharma and Lannett Company mutually agreed on June 23, 2026 to terminate their exclusive Metadate CD license agreement, except for provisions that survive under a new Termination Agreement. Aytu may keep selling existing inventory at its discretion but must continue royalty reports and payments until those sales cease. The filing reports Metadate CD net revenue of $49,000 for the quarter ended March 31, 2026.
Key points
- Termination effective June 23, 2026, by mutual agreement with Lannett Company, Inc.
- Metadate Agreement dated May 11, 2022, amended July 6, 2023 and July 17, 2025, is terminated in its entirety apart from surviving provisions.
- Aytu may sell existing inventory at its sole discretion and must keep providing royalty reports and paying royalties until sales cease.
- Metadate CD net revenue was $49,000 for the quarter ended March 31, 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.